Sign in
CompletedPhase 2/3

Strong Albumin Solutions in Patients With Septic Shock

Key facts

Who runs it
Manchester University NHS Foundation Trust
Where
United Kingdom2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 2/3
People taking part
47 people enrolled
Started
10 Nov 2023
Ended
31 Jan 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • hyperoncotic human albumin solution
  • Buffered crystalloid solutions
Record updated
9 February 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Suspected or documented infection
  • Organ dysfunction defined as SOFA score ≥2
  • Need for vasopressor infusion for ≥2 hours
  • Serum lactate ≥2 mmol/L
  • Eligible for critical care admission without any restrictions

Who cannot take part

  • Previous enrolment in this study
  • Patients with a known allergy to albumin
  • Previous receipt of human albumin solution for the episode of sepsis in question
  • <18 years of age
  • >24 hours since the time point of meeting all inclusion criteria
  • Pregnancy
  • Jehova's witnesses or other patients expressing a known objection to the use of blood products

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Sepsis is an increasingly recognised burden to healthcare systems worldwide. Intravenous fluid therapy is a common first-line intervention recommended by international guidelines. Hyperoncotic preparations of human albumin solution are widely available, but their efficacy has yet to be proven.

Read full original descriptionShow less

This randomised feasibility trial will test whether it is feasible to administer hyperoncotic albumin solutions as both fluid resuscitation and as a regular supplement in patients with early septic shock.

The 2 groups in the trial

  • Hyperoncotic albuminTreatment being tested

    Hyperoncotic albumin for all fluid resuscitation and also as a daily supplement, guided by daily serum albumin values, for up to 7 days.

    Treatment: hyperoncotic human albumin solution

  • Buffered crystalloidsExisting treatment, for comparison

    Buffered crystalloid solutions for all fluid resuscitation and maintenance purposes. Participants in this arms will NOT receive any albumin during their participation.

    Treatment: Buffered crystalloid solutions

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Small Volume Fluid Resuscitation and Supplementation With 20% albumIn Versus Buffered Crystalloids in PatiEnts With Septic Shock
Record updated
9 February 2026